Cancer Stem Cell News Volume 9.25 | Jul 8 2020







2020-07-08 | CSCN 9.25


Cancer Stem Cell News by STEMCELL Technologies
Vol. 9.25 – 8 July, 2020
TOP STORY

Single-Cell RNA-Seq Reveals that Glioblastoma Recapitulates a Normal Neurodevelopmental Hierarchy

Investigators found a conserved neural tri-lineage cancer hierarchy centered around glial progenitor-like cells. They also found that this progenitor population contained the majority of the cancer’s cycling cells, and, using RNA velocity, was often the originator of the other cell types.
[Nature Communications]

Full Article

Subscribe to Science News for free weekly science newsletters.
PUBLICATIONSRanked by the impact factor of the journal

Integrated Pharmaco-Proteogenomics Defines Two Subgroups in Isocitrate Dehydrogenase Wild-Type Glioblastoma with Prognostic and Therapeutic Opportunities

Researchers describe a distinct binary classification of isocitrate dehydrogenase 1/2 (IDH) wild-type glioblastoma (GBM) tumors derived from a quantitative proteomic analysis of 39 IDH wild-type GBMs as well as IDH mutant and low-grade glioma controls.
[Nature Communications]

Full Article

JAM-A Functions as a Female Microglial Tumor Suppressor in Glioblastoma

Investigators studied the role of microenvironmental junctional adhesion molecule-A (JAM-A) in mediating glioblastoma growth.
[Neuro-Oncology]

Abstract

Protein Sumoylation with SUMO1 Promoted by Pin1 in Glioma Stem Cells Augments Glioblastoma Malignancy

Researchers investigated the protein sumoylation status, the major sumoylated substrate and the key regulatory enzyme in glioma stem cells to explore the therapeutic potential of disrupting protein sumoylation for glioblastoma treatment.
[Neuro-Oncology]

Abstract

Melanoma Stem Cell Maintenance and Chemo-Resistance Are Mediated by CD133 Signal to PI3K-Dependent Pathways

The functional analysis of CD133+ and CD133 cells in vitro and in vivo revealed that melanoma progression and treatment resistance are the consequences of CD133 signal to PI3K pathway.
[Oncogene]

Abstract

CDK5RAP3 as Tumor Suppressor Negatively Regulates Self-Renewal and Invasion and Is Regulated by ERK1/2 Signaling in Human Gastric Cancer

Researchers showed that CDK5 regulatory subunit-associated protein 3 was weakly expressed in gastric cancer stem-like cells (CSCs) and was negatively correlated with the gastric CSC marker CD44.
[British Journal of Cancer]

Abstract

MiR-1976 Knockdown Promotes Epithelial–Mesenchymal Transition and Cancer Stem Cell Properties Inducing Triple-Negative Breast Cancer Metastasis

In a self-established mouse model consisting normal human breast tissues and normal human bone tissues, triple-negative breast cancer cell line SUM-1315 could spontaneously form species-specific bone metastasis.
[Cell Death & Disease]

Full Article

miR-146b-5p Suppresses the Malignancy of GSC/MSC Fusion Cells by Targeting SMARCA5

miR-146b-5p was downregulated in glioma stem-like cell/mesenchymal stem cell fusion cells, and its overexpression suppressed proliferation, migration and invasion by the fusion cells.
[Aging]

Full Article

Exosomal MiR‐500a‐3p Promotes Cisplatin Resistance and Stemness via Negatively Regulating FBXW7 in Gastric Cancer

Researchers found that microRNA‐500a‐3p was highly expressed in cisplatin resistant gastric cancer cells and their secreted exosomes than that in the corresponding parental cells.
[Journal of Cellular and Molecular Medicine]

Full Article

TGF-β Induced EMT and Stemness Characteristics are Associated with Epigenetic Regulation in Lung Cancer

Scientists determined whether EMT and stemness characteristics induced by TGF-β might be associated with epigenetic regulation in lung cancer.
[Scientific Reports]

Full Article


Dr. Kristina McBurney and Leanna Bedell discuss how you can use social media to advance your scientific career. Watch now.
REVIEWS

The CCL5/CCR5 Axis in Cancer Progression

Researchers summarize current knowledge on the role of the C-C chemokine ligand 5/C-C chemokine receptor type 5 (CCL5/CCR5) axis in cancer.
[Cancers]

Full Article

INDUSTRY AND POLICY NEWS

Ziopharm Oncology Doses First DIPG Patient in Phase I/II Trial of Controlled IL-12 for the Treatment of Pediatric Brain Tumors

Ziopharm Oncology, Inc. announced that the first patient with diffuse intrinsic pontine glioma has been dosed in its Phase I/II study of Ad-RTS-hIL-12 with veledimex for the treatment of pediatric brain tumors.
[ZIOPHARM Oncology Inc.]

Press Release

An Optimist Takes the Helm at the National Science Foundation

The new director of the National Science Foundation (NSF), Sethuraman “Panch” Panchanathan, is familiar with the dark clouds over the agency. His boss, President Donald Trump, keeps proposing big cuts to NSF’s budget. Two recent executive orders on immigration make it harder for foreign scientists—who make up a sizeable share of the U.S. research enterprise—to enter the country.
[Science]

Editorial

FEATURED EVENT

International Society for Stem Cell Research (ISSCR): Advances in Stem Cell Research: From Single Cells to Organs

October 12 – October 14
Paris, France

> See All Events

JOB OPPORTUNITIES

Postdoctoral Researcher – RNA Epitranscriptomics and Immune Cells

Lund University – Lund, Sweden

Postdoctoral Research Fellowship – Cancer Biology

Massachusetts General Hospital – Charlestown, Massachusetts, United States

Faculty and Postdoctoral Positions – Stem Cells and Cancer

Shanghai Jiao Tong University – Shanghai, China

Postdoctoral Fellow – Molecular Diagnostics and Experimental Therapeutics

City of Hope – Monrovia, California, United States

Postdoctoral Position – Epigenetic Control of Cancer Stem Cell Biology

University of Freiburg – Freiburg, Germany

> See All Jobs

Submit an article, publication, job or event
Brought to you by
stemcell-logo-for newsletter-2
Cancer Stem Cell News Twitter


0
Share